Evidence map›Paper›PMID 33244245›Full record

ArticleInfection and drug resistance2020

Optimal Empiric Treatment for

Yuhong Jin, Haiyan Mao, Bingyang Liu, Fen Zhou, Junjie Yang, Lei Xu, Jingtao Tong, Chen Huang, Yi Ding

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuhong JinDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Haiyan MaoDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Bingyang LiuDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Fen ZhouDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Junjie YangDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Lei XuDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Jingtao TongDepartment of Radiotherapy, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Chen HuangDepartment of Respiratory Medicine, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.
Yi DingDepartment of Intensive Care, Lihuili Hospital, Ningbo Medical Center, Ningbo, People's Republic of China.ORCID 0000-0001-7856-9772
Ningbo Medical Center Lihuili Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThere is a paucity of published data to evaluate the efficacy and safety of imipenem (IPM) and piperacillin-tazobactam (PT) dosing regimens in the treatment of septic patients acquiring continuous renal replacement therapy (CRRT). METHODS AND MATERIALS: Critically-ill patients were grouped into short-stay and long-stay intensive care unit (ICU) patients. Pathogens were isolated from bloodstream infections in these patients. Minimum inhibitory concentration (MIC) value was determined by agar dilution method. Population PK models were introduced in this study, and differences in the likelihood of achieving efficacious and toxic exposures of IPM and PT for critically-ill patients were assessed.

resultsA total of 86

conclusionNo dose adjustment was required for the conventional IMP and PT regimens in the critically-ill population acquiring CRRT. Empirical treatment of IMP 0.5g q8h/q6h, not for PT, may provide sufficient antimicrobial exposure for short-stay ICU patients during CRRT. PT should be used in the knowledge of MIC results.

Indexed as

continuous renal replacement therapy; CRRTintensive care unit; ICUKlebsiella pneumoniae infectionpharmacokinetic/pharmacodynamic

Identifiers

PMID33244245
PMCPMC7683353
OpenAlexW3103165157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.